Search

Your search keyword '"De Maria, V"' showing total 22 results
Start Over Author "De Maria, V"
22 results on '"De Maria, V"'

4. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Author

Ascione, A, Adinolfi, L, Amoroso, P, Andriulli, A, Armignacco, O, Ascione, T, Babudieri, S, Barbarini, G, Brogna, M, Cesario, F, Citro, V, Claar, E, Cozzolongo, R, D'Adamo, G, D'Amico, E, Dattolo, P, De Luca, M, De Maria, V, De Siena, M, De Vita, G, Di Giacomo, A, De Marco, R, De Stefano, G, Di Salvo, S, Di Sarno, R, Farella, N, Felicioni, L, Fimiani, B, Fontanella, L, Foti, G, Furlan, C, Giancotti, F, Giolitto, G, Gravina, T, Guerrera, B, Gulminetti, R, Iacobellis, A, Imparato, M, Iodice, A, Iovinella, V, Izzi, A, Liberti, A, Leo, P, Lettieri, G, Luppino, I, Marrone, A, Mazzoni, E, Messina, V, Monarca, R, Narciso, V, Nosotti, L, Pellicelli, A, Perrella, A, Piai, G, Picardi, A, Pierri, P, Pietromatera, G, Resta, F, Rinaldi, L, Romano, M, Rossini, A, Russello, M, Russo, G, Sacco, R, Sangiovanni, V, Schiano, A, Sciambra, A, Scifo, G, Simeone, F, Sullo, A, Tarquini, P, Tundo, P, Vallone, A, Ascione A., Adinolfi L. E., Amoroso P., Andriulli A., Armignacco O., Ascione T., Babudieri S., Barbarini G., Brogna M., Cesario F., Citro V., Claar E., Cozzolongo R., D'Adamo G., D'Amico E., Dattolo P., De Luca M., De Maria V., De Siena M., De Vita G., Di Giacomo A., De Marco R., De Stefano G., Di Salvo S., Di Sarno R., Farella N., Felicioni L., Fimiani B., Fontanella L., Foti G., Furlan C., Giancotti F., Giolitto G., Gravina T., Guerrera B., Gulminetti R., Iacobellis A., Imparato M., Iodice A., Iovinella V., Izzi A., Liberti A., Leo P., Lettieri G., Luppino I., Marrone A., Mazzoni E., Messina V., Monarca R., Narciso V., Nosotti L., Pellicelli A. M., Perrella A., Piai G., Picardi A., Pierri P., Pietromatera G., Resta F., Rinaldi L., Romano M., Rossini A., Russello M., Russo G., Sacco R., Sangiovanni V., Schiano A., Sciambra A., Scifo G., Simeone F., Sullo A., Tarquini P., Tundo P., Vallone A., Ascione, A, Adinolfi, L, Amoroso, P, Andriulli, A, Armignacco, O, Ascione, T, Babudieri, S, Barbarini, G, Brogna, M, Cesario, F, Citro, V, Claar, E, Cozzolongo, R, D'Adamo, G, D'Amico, E, Dattolo, P, De Luca, M, De Maria, V, De Siena, M, De Vita, G, Di Giacomo, A, De Marco, R, De Stefano, G, Di Salvo, S, Di Sarno, R, Farella, N, Felicioni, L, Fimiani, B, Fontanella, L, Foti, G, Furlan, C, Giancotti, F, Giolitto, G, Gravina, T, Guerrera, B, Gulminetti, R, Iacobellis, A, Imparato, M, Iodice, A, Iovinella, V, Izzi, A, Liberti, A, Leo, P, Lettieri, G, Luppino, I, Marrone, A, Mazzoni, E, Messina, V, Monarca, R, Narciso, V, Nosotti, L, Pellicelli, A, Perrella, A, Piai, G, Picardi, A, Pierri, P, Pietromatera, G, Resta, F, Rinaldi, L, Romano, M, Rossini, A, Russello, M, Russo, G, Sacco, R, Sangiovanni, V, Schiano, A, Sciambra, A, Scifo, G, Simeone, F, Sullo, A, Tarquini, P, Tundo, P, Vallone, A, Ascione A., Adinolfi L. E., Amoroso P., Andriulli A., Armignacco O., Ascione T., Babudieri S., Barbarini G., Brogna M., Cesario F., Citro V., Claar E., Cozzolongo R., D'Adamo G., D'Amico E., Dattolo P., De Luca M., De Maria V., De Siena M., De Vita G., Di Giacomo A., De Marco R., De Stefano G., Di Salvo S., Di Sarno R., Farella N., Felicioni L., Fimiani B., Fontanella L., Foti G., Furlan C., Giancotti F., Giolitto G., Gravina T., Guerrera B., Gulminetti R., Iacobellis A., Imparato M., Iodice A., Iovinella V., Izzi A., Liberti A., Leo P., Lettieri G., Luppino I., Marrone A., Mazzoni E., Messina V., Monarca R., Narciso V., Nosotti L., Pellicelli A. M., Perrella A., Piai G., Picardi A., Pierri P., Pietromatera G., Resta F., Rinaldi L., Romano M., Rossini A., Russello M., Russo G., Sacco R., Sangiovanni V., Schiano A., Sciambra A., Scifo G., Simeone F., Sullo A., Tarquini P., Tundo P., and Vallone A.

Abstract

AIM: To check the safety and efficacy of boceprevir/ telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-TaqMan2.0 (Roche, LLQ 25 IU/mL). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57 (range 18-78), of whom 18.3% were over 65; mean body mass index 25.6 (range 16-39); genotype 1b (79.4%); diagnosis of cirrhosis (38.2%); and fibrosis F3/4 (71.2%). The following drugs were used: Telaprevir (66.2%) and PEG-IFN-alpha2a (67.6%). Patients were naïve (24.4%), relapsers (30.5%), partial responders (14.8%) and null responders (30.3%). Overall, adverse events (AEs) occurred in 617 patients (73.9%) during the treatment. Anemia was the most frequent AE (52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure (15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin.

Published
2016

5. ITALIAN CANCER FIGURES - REPORT 2015: The burden of rare cancers in Italy = I TUMORI IN ITALIA - RAPPORTO 2015: I tumori rari in Italia

Author

Busco, Susanna, Buzzoni, Carlotta, Mallone, Sandra, Trama, Annalisa, Castaing, Marine, Bella, Francesca, Amodio, Rosalba, Bizzoco, Sabrina, Cassetti, Tiziana, Cirilli, Claudia, Cusimano, Rosanna, De Angelis, Roberta, Fusco, Mario, Gatta, Gemma, Gennaro, Valerio, Giacomin, Adriano, Giorgi Rossi, Paolo, Mangone, Lucia, Mannino, Salvatore, Rossi, Silvia, Pierannunzio, Daniela, Tavilla, Andrea, Tognazzo, Sandro, Tumino, Rosario, Vicentini, Massimo, Vitale, Maria Francesca, Crocetti, Emanuele, Dal Maso, Luigino, Mazzoleni, G, Bulatko, A, Devigili, E, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Vittadello, F, Coviello, V, Cuccaro, F, Calabrese, A, Pinto, A, Cannone, G, Vitali, Me, Sampietro, G, Ghisleni, S, Giavazzi, L, Zanchi, A, Zucchi, A, Giacomin, A, Vercellino, Pc, Andreone, S, Fedele, M, Barale, A, Germinetti, F, Magoni, M, Zani, G, Salvi, O, Puleio, M, Gerevini, C, Adorni, A, Chiesa, R, Lonati, F, Tumino, R, Cascone, G, Frasca, G, Giurdanella, Mc, Martorana, C, Morana, G, Nicita, C, Rollo, Pc, Ruggeri, Mg, Spata, E, Vacirca, S, Sciacca, S, Sciacchitano, C, Fidelbo, M, Paderni, F, Benedetto, G, Vasquez, E, Bella, F, Calabretta, L, Castaing, M, Di Prima, A, Ieni, A, Leone, A, Pesce, P, Sciacchitano, S, Torrisi, A, Varvarà, M, Sutera Sardo, A, Mazzei, A, Lavecchia, Am, Mancuso, P, Nocera, V, Gola, G, Corti, M, Grandi, L, Caparelli, M, Mannino, S, Belluardo, C, Bizzoco, S, Davini, C, Lucchi, S, Villa, M, Anghinoni, E, Di Norcia, R, Ferretti, S, Biavati, P, Marzola, L, Migliari, E, Carletti, N, Petrucci, C, Brosio, F, Piccinni, L, Valente, N, Barchielli, A, Buzzoni, C, Caldarella, A, Corbinelli, A, Di Dia PP, Intrieri, T, Manneschi, G, Nemcova, L, Susini, N, Visoli, C, Zappa, M, Serraino, D, Angelin, T, Bidoli, E, Birri, S, Dal Maso, L, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Filiberti, Ra, Casella, C, Marani, E, Puppo, A, Celesia, Mv, Cogno, R, Garrone, E, Pannozzo, F, Busco, S, Rashid, I, Ramazzotti, V, Cercato, Mc, Natali, M, Battisti, W, Sperduti, I, Macci, L, Bugliarello, E, Bernazza, E, Tamburo, L, Rossi, M, Curatella, S, Tamburrino, S, Fattoruso, S, Valerio, O, Melcarne, A, Quarta, F, Golizia, Mg, Raho, Am, De Maria, V, Vitarelli, S, Ricci, P, Guarda, L, Gatti, L, Pironi, V, Pasolini, A, Bordini, M, Autelitano, M, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Russo, Ag, Quattrocchi, M, Distefano, R, Panciroli, E, Bellini, A, Pinon, M, Spinosa, S, Spagnoli, G, Goldoni, Ca, Valla, K, Braghiroli, B, Cirilli, C, Donini, M, Amendola, V, Cavalieri d'Oro, L, Rognoni, M, Le Rose, L, Merlo, E, Negrino, L, Pezzuto, L, Fusco, M, Bellatalla, C, Panico, M, Perrotta, C, Vassante, B, Vitale, Mf, Usala, M, Pala, F, Sini, Gm, Pintori, N, Canu, L, Demurtas, G, Doa, N, Vitale, F, Cusimano, R, Traina, A, Guttadauro, A, Cascio, Ma, Mannino, R, Ravazzolo, B, Brucculeri, Ma, Rudisi, G, Adamo, Ms, Amodio, R, Costa, A, Zarcone, M, Sunseri, R, Bucalo, G, Trapani, C, Staiti, R, Michiara, M, Bozzani, F, Sgargi, P, Borciani, E, Seghini, P, Faccini, F, Prazzoli, R, Mangone, L, Di Felice, E, Pezzarossi, A, Caroli, S, Sacchettini, C, Ferrari, F, Roncaglia, F, Vicentini, M, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Caiazzo, Al, Cavallo, R, Colavolpe, Af, D'Alessandro, A, Iannelli, A, Lombardo, C, Senatore, G, Sensi, F, Cesaraccio, R, Sechi, O, Pirino, D, Mura, F, Contrino, Ml, Madeddu, A, Tisano, F, Muni, A, Dinaro, Y, Mizzi, M, Sacco, G, Aletta, P, Ziino, Ac, Maspero, S, Fanetti, Ac, Moroni, E, Cometti, I, Annulli, Ml, Cecconami, L, Minerba, S, Minicuzzi, A, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Sacchetto, L, Candela, G, Scuderi, T, Crapanzano, G, Taranto, V, Piffer, S, Gentilini, Ma, Rizzello, R, Cappelletti, M, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, Am, Solimene, C, Bianconi, F, Brunori, V, Tagliabue, G, Contiero, P, Tittarelli, A, Fabiano, S, Maghini, A, Codazzi, T, Frassoldi, E, Gada, D, di Grazia, L, Ruzza, Mr, Dei Tos AP, Baracco, M, Baracco, S, Bovo, E, Dal Cin, A, Fiore, Ar, Greco, A, Guzzinati, S, Monetti, D, Rosano, A, Stocco, C, Tognazzo, S, Zorzi, M, Merletti, F, Magnani, C, Pastore, G, Terracini, B, Alessi, D, Cena, T, Lazzarato, F, Macerata, V, Maule, M, Mosso, Ml, Sacerdote, C, Cocchioni, M, Pascucci, C, Ponz de Leon, M, Domati, F, Rossi, G, Kaleci, S, Rossi, F, Benatti, P, Roncucci, L, Di Gregorio, C, Magnani, G, Pedroni, M, Maffei, S, Mariani, F, Reggiani-Bonetti, L, Gennaro, V, Benfatto, L, Lando, C, Mazzucco, G, Romanelli, A, Storchi, C, Sala, O, Gabbi, C, and Buzzoni, C.

Published
2016

6. I TUMORI IN ITALIA - RAPPORTO 2013: Tumori multipli = ITALIAN CANCER FIGURES - REPORT 2013: Multiple tumours

Author

Adamo, Ms, Alessi, D, Aletta, P, Amodio, R, Andreone, S, Angelin, T, Anghinoni, E, Annulli, Ml, Antonini, S, Artioli, Me, Autelitano, M, Balducci, C, Balottari, P, Baracco, M, Battisti, W, Bella, F, Bellatalla, C, Belluardo, C, Benatti, P, Benedetto, G, Benfatto, L, Bernazza, E, Bianconi, F, Biavati, P, Bidoli, E, Birri, S, Bizzoco, S, Bonelli, L, Bonini, A, Borciani, E, Bovo, E, Bozzani, F, Bozzeda, A, Braghiroli, B, Brucculeri, Ma, Brunori, V, Bucalo, G, Bucchi, L, Bugliarello, E, Bulatko, A, Busco, S, Busso, P, Buzzoni, C, Calabretta, L, Caldarella, A, Candela, G, Canu, L, Cappelletti, M, Caprara, L, Carboni, D, Carletti, N, Caroli, S, Carone, S, Cascio, Ma, Cascone, G, Casella, C, Castaing, M, Cecconami, L, Celesia, Mv, Cena, T, Cercato, Mc, Cesaraccio, R, Chiesa, R, Cirilli, C, Civaschi, A, Cocchioni, Mario, Codazzi, T, Cogno, R, Colamartini, A, Colanino Ziino, A, Cometti, I, Contiero, P, Contrino, Ml, Corbinelli, A, Cordaro, C, Corti, M, Costa, A, Costarelli, D, Cremone, L, Crocetti, E, Curatella, S, Cusimano, R, D'Alò, D, D'Angelo, S, Dal Cappello, T, Dal Cin, A, Dal Maso, L, Dall'Acqua, M, Dalsasso, F, Davini, C, De Dottori, M, De Maria, V, De Santis, E, De Valiere, E, Dei Tos AP, Demurtas, G, Devigli, E, Di Felice, E, di Grazia, L, Di Gregorio, C, Di Prima, A, Distefano, R, Doa, N, Domati, F, Fabiano, S, Facchinelli, G, Falcini, F, Falk, M, Fanetti, Ac, Fattoruso, S, Federico, M, Ferrari, L, Ferretti, S, Fidelbo, M, Filipazzi, L, Fiore, Ar, Fiori, G, Foca, F, Forgiarini, O, Frasca, G, Frassoldi, E, Frizza, J, Fusco, M, Gada, D, Garrone, E, Gasparotti, C, Gatti, L, Gaudiano, C, Gennaro, V, Gentilini, M, Gerevini, C, Ghilardi, S, Ghisleni, S, Giacomin, A, Giavazzi, L, Gilardi, F, Giorgetti, S, Giubelli, C, Giuliani, O, Giurdanella, Mc, Gola, G, Goldoni, Ca, Golizia, Mg, Grandi, L, Greco, A, Guarda, L, Guttadauro, A, Guzzinati, S, Iachetta, F, Iannelli, A, Ieni, A, Intrieri, T, Kaleci, S, La Rosa, F, Lando, C, Lavecchia, Am, Lazzarato, F, Leone, A, Leone, R, Lonati, F, Lottero, B, Lucchi, S, Luminari, S, Macci, L, Macerata, V, Madeddu, A, Maffei, S, Maghini, A, Magnani, C, Magnani, G, Magoni, M, Mameli, G, Mancini, S, Mancuso, P, Mangone, L, Manneschi, G, Mannino, R, Mannino, S, Marani, E, Mariani, F, Martorana, C, Marzola, L, Maspero, S, Maule, M, Mazzei, A, Mazzoleni, G, Mazzucco, G, Melcarne, A, Merletti, F, Michiara, M, Migliari, E, Minerba, S, Minicuzzi, A, Mizzi, M, Monetti, D, Morana, G, Moroni, E, Mosso, Ml, Muni, A, Mura, F, Natali, M, Nemcova, L, Nicita, C, Ocello, C, Paci, E, Pala, F, Palumbo, M, Panico, M, Pannozzo, F, Pascucci, Cristiana, Pastore, G, Patriarca, S, Pedroni, M, Pellegri, C, Perrotta, C, Pesce, P, Petrinelli, Am, Petrucci, C, Pezzarossi, A, Piffer, S, Pintori, N, Pirani, M, Pirino, D, Pironi, V, Ponz de Leon, M, Prandi, R, Prazzoli, R, Preto, L, Puleio, M, Puppo, A, Quaglia, A, Quarta, F, Quattrocchi, M, Raho, Am, Ramazzotti, V, Rashid, I, Ravaioli, A, Ravazzolo, B, Ravegnani, M, Reggiani Bonetti, L, Ribaudo, M, Rinaldi, E, Ricci, P, Rizzello, R, Rollo, Pc, Roncucci, L, Rosano, A, Rossi, F, Rossi, G, Rossi, M, Rossini, S, Rosso, S, Rudisi, G, Ruggeri, Mg, Russo, Ag, Russo, M, Sacchettini, C, Sacco, G, Sacerdote, C, Salvatore, S, Salvi, O, Sampietro, G, Sandrini, M, Santucci, C, Scheibel, M, Schiacchitano, S, Sciacca, S, Sciacchitano, C, Scuderi, T, Sechi, O, Seghini, P, Senatore, G, Serafini, G, Serraino, D, Sgargi, P, Sigona, A, Sini, Gm, Sobrato, I, Soddu, M, Solimene, C, Spano, F, Spata, E, Sperduti, I, Staiti, R, Stocco, C, Stracci, F, Sunseri, R, Sardo, As, Tagliabue, G, Tamburo, L, Tamburrino, S, Tanzarella, M, Terracini, B, Tessandori, R, Tisano, F, Tittarelli, A, Tognazzo, S, Torrisi, A, Traina, A, Trapani, C, Tschugguel, B, Tumino, R, Usala, M, Vacirca, S, Valerio, O, Valla, K, Varvarà, M, Vasquez, E, Vassante, B, Vattiato, R, Vercelli, M, Vercellino, Pc, Vicentini, M, Villa, M, Vitale, F, Vitale, Mf, Vitali, B, Vitarelli, Susanna, Zanchi, A, Zanetti, R, Zani, G, Zanier, L, Zappa, M, Zarcone, M, Zevola, A, Zucchetto, A, and Zucchi, A.

Published
2013

7. Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study

Author

Kondili, L., primary, Quaranta, M.G., additional, Falzano, L., additional, Di Gregorio, M., additional, Brunetto, M., additional, Zignego, A.L., additional, Ciancio, A., additional, Di Leo, A., additional, Rendina, M., additional, Raimondo, G., additional, Ferrari, C., additional, Craxì, A., additional, Taliani, G., additional, Borgia, G., additional, Gentile, I., additional, Santantonio, T.A., additional, Giammario, A., additional, Blanc, P., additional, Gaeta, G.B., additional, Gasbarrini, A., additional, Siciliano, M., additional, Chessa, L., additional, Erne, E.M., additional, Ieluzzi, D., additional, Russo, F.P., additional, Andreone, P., additional, Vinci, M., additional, Coppola, C., additional, Chemello, L., additional, Madonia, S., additional, Verucchi, G., additional, Persico, M., additional, Zuin, M., additional, Alberti, A., additional, Puoti, M., additional, Nardone, G., additional, De Maria, V., additional, Massari, M., additional, Montalto, G., additional, Foti, G., additional, Rumi, M.G., additional, Giacometti, A., additional, Benedetti, A., additional, D’Offizi, G., additional, Strazzabosco, M., additional, Fargion, S., additional, Angarano, G., additional, Federico, A., additional, Caporaso, N., additional, Mastroianni, C., additional, Toniutto, P., additional, Colombo, M., additional, Lazzarin, A., additional, Torti, C., additional, Andreoni, M., additional, Rosina, F., additional, Viscoli, C., additional, Vella, S., additional, and Villa, E., additional

Published
2016
Full Text
View/download PDF

8. FRI-180 - Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study

Author

Kondili, L., Quaranta, M.G., Falzano, L., Di Gregorio, M., Brunetto, M., Zignego, A.L., Ciancio, A., Di Leo, A., Rendina, M., Raimondo, G., Ferrari, C., Craxì, A., Taliani, G., Borgia, G., Gentile, I., Santantonio, T.A., Giammario, A., Blanc, P., Gaeta, G.B., Gasbarrini, A., Siciliano, M., Chessa, L., Erne, E.M., Ieluzzi, D., Russo, F.P., Andreone, P., Vinci, M., Coppola, C., Chemello, L., Madonia, S., Verucchi, G., Persico, M., Zuin, M., Alberti, A., Puoti, M., Nardone, G., De Maria, V., Massari, M., Montalto, G., Foti, G., Rumi, M.G., Giacometti, A., Benedetti, A., D’Offizi, G., Strazzabosco, M., Fargion, S., Angarano, G., Federico, A., Caporaso, N., Mastroianni, C., Toniutto, P., Colombo, M., Lazzarin, A., Torti, C., Andreoni, M., Rosina, F., Viscoli, C., Vella, S., and Villa, E.

Published
2016
Full Text
View/download PDF

9. Trends in Lung Cancer and Smoking Behavior in Italy: An Alarm Bell for Women

Author

Trama, Annalisa, Boffi, Roberto, Contiero, Paolo, Buzzoni, Carlotta, Pacifici, Roberta, Mangone, Lucia, Coviello, V, Buzzoni, C, Fusco, M, Barchielli, A, Cuccaro, F, De Angelis, R, Giacomin, A, Luminari, S, Randi, G, Mangone, L, Mazzoleni, G, Bulatko, A, Devigili, E, Tschugguel, B, De Valiere, E, Facchinelli, G, Falk, M, Vittadello, F, Coviello, V, Cuccaro, F, Calabrese, A, Pinto, A, Cannone, G, Vitali, ME, Galasso, R, Del Riccio, L, Napolitano, D, Sampietro, G, Ghisleni, S, Giavazzi, L, Zanchi, A, Zucchi, A, Giacomin, A, Vercellino, PC, Andreone, S, Fedele, M, Barale, A, Germinetti, F, Magoni, M, Salvi, O, Puleio, M, Gerevini, C, Chiesa, R, Lonati, F, Cavalieri d'Oro, L, Rognoni, M, Le Rose, L, Merlo, E, Bracchi, A, Negrino, L, Pezzuto, L, Ardizzone, A, Spagnolo, G, Cozzi, E, De Lorenzism, L, Lotti, F, Pagliara, MC, D'Argenzio, A, D'Abronzo, M, De Francesco, D, Pereira da Silva, MCM, Menditto, V, Perrotta, E, Pesce, MT, Sessa, A, Sciacca, S, Sciacchitano, S, Fidelbo, M, Benedetto, G, Benedetto, A, Calabretta, LMR, Caruso, AM, Castaing, M, Di Prima, AA, Dinaro, YM, Fidelbo, P, Grosso, G, Ippolito, A, Irato, E, Leone, A, Paderni, F, Pesce, PNR, Pollina Addario, S, Savasta, A, Sciacchitano, CG, Torrisi, AAM, Torrisi, A, Varvarà, M, Viscosi, C, Sutera Sardo, A, Sia, A, Scalzi, S, Lavecchia, AM, Mancuso, P, Nocera, V, Mancusi, F, Del Duca, S, Gola, G, Corti, M, Caparelli, M, Ferretti, S, Marzola, L, Migliari, E, Carletti, N, Biavati, P, Petrucci, C, Serraino, D, Angelin, T, Bidoli, E, Birri, S, Dal Maso, L, De Dottori, M, De Santis, E, Forgiarini, O, Zucchetto, A, Zanier, L, Pannozzo, F, Busco, S, Rossi, M, Curatella, S, Bugliarello, E, Macci, L, Bernazza, E, Calabretta, F, Tamburrino, S, Sperduti, I, Tamburo, L, Serafini, G, Quarta, F, Melcarne, A, Golizia, MG, Arciprete, C, De Maria, V, Filiberti, RA, Casella, C, Marani, E, Puppo, A, Celesia, MV, Cogno, R, Vitarelli, S, Ricci, P, Autelitano, M, Ghilardi, S, Leone, R, Filipazzi, L, Bonini, A, Giubelli, C, Russo, AG, Quattrocchi, M, Distefano, R, Panciroli, E, Bellini, A, Pinon, M, Spinosa, S, Spagnoli, G, Carrozzi, G, Cirilli, C, Valla, K, Amendola, V, Fusco, M, Bellatalla, C, Ciullo, V, Di Buono, M, Fusco, M, Panico, M, Perrotta, C, Vitale, MF, Usala, M, Pala, F, Sini, GM, Pintori, N, Canu, L, Demurtas, G, Doa, N, Vitale, F, Cusimano, R, Traina, A, Guttadauro, A, Cascio, MA, Mannino, R, Ravazzolo, B, Brucculeri, MA, Rudisi, G, Adamo, MS, Amodio, R, Costa, A, Zarcone, M, Sunseri, R, Bucalo, G, Trapani, C, Staiti, R, Michiara, M, Bozzani, F, Sgargi, P, Boschetti, L, Migliazza, S, Reggiani, E, Incardona, N, Borciani, E, Seghini, P, Prazzoli, R, Zanetti, R, Rosso, S, Patriarca, S, Prandi, R, Sobrato, I, Gilardi, F, Busso, P, Sacchetto, L, Tumino, R, Cascone, G, Frasca, G, Giurdanella, MC, Martorana, C, Morana, G, Nicita, C, Rollo, PC, Ruggeri, MG, Spata, E, Vacirca, S, Mangone, L, Vicentini, M, Di Felice, E, Pezzarossi, A, Ferrari, F, Roncaglia, F, Sacchettini, C, Caroli, S, Falcini, F, Colamartini, A, Bucchi, L, Balducci, C, Ravegnani, M, Vitali, B, Cordaro, C, Caprara, L, Giuliani, O, Giorgetti, S, Palumbo, M, Vattiato, R, Ravaioli, A, Mancini, S, Caiazzo, AL, Cavallo, R, Colavolpe, AFG, D'Alessandro, A, Iannelli, A, Lombardo, C, Senatore, G, Sensi, F, Cesaraccio, R, Pirino, D, Mura, F, Contrino, ML, Madeddu, A, Tisano, F, Dinaro, Y, Muni, A, Mizzi, M, Bella, F, Rossitto, L, Sacco, G, Aletta, P, Colanino Ziino, A, Maspero, S, Fanetti, AC, Cometti, I, Cecconami, L, Minerba, S, Mincuzzi, A, Carone, S, Tanzarella, M, Galluzzo, C, Barchielli, A, Buzzoni, C, Caldarella, A, Corbinelli, A, Intrieri, T, Di Dia, PP, Manneschi, G, Nemcova, L, Visioli, C, Zappa, M, Candela, G, Scuderi, T, Crapanzano, G, Taranto, V, Piffer, S, Gentilini, M, Rizzello, R, Bombarda, L, Pedron, M, Clivati, E, Stracci, F, D'Alò, D, Scheibel, M, Costarelli, D, Spano, F, Rossini, S, Santucci, C, Petrinelli, AM, Solimene, C, Bianconi, F, Brunori, V, Tagliabue, G, Contiero, P, Tittarelli, A, Fabiano, S, Maghini, A, Codazzi, T, Barigelletti, G, D'Agostino, A, Modonesi, C, Rugge, M, Baracco, M, Baracco, S, Bovo, E, Dal Cin, A, Fiore, AR, Greco, A, Guzzinati, S, Martin, G, Memo, L, Monetti, D, Rizzato, S, Rosano, A, Stocco, C, Tognazzo, S, Zorzi, M, Brustolin, A, Beggiato, S, Aniceti, S, Fiocchetti, L, Schirra, G, Galeotti, P, Capati, A, Nami, A, Montanaro, M, Verrico, G, Poleggi, F, Rashid, I, Grappasonni, I, Pascucci, C, Merletti, F, Magnani, C, Pastore, G, Terracini, B, Alessi, D, Cena, T, Lazzarato, F, Macerata, V, Maule, M, Mosso, ML, Sacerdote, C, Romanelli, A, Mangone, L, Storchi, C, Sala, O, Gabbi, C, Gennaro, V, Benfatto, L, Malacarne, D, Lando, C, Campi, MG, Mazzucco, G, Ponz de Leon, M, Domati, F, Rossi, G, Goldoni, CA, Kaleci, S, Rossi, F, Benatti, P, Roncucci, L, Di Gregorio, C, Magnani, G, Pedroni, M, Maffei, S, Mariani, F, Reggiani-Bonetti, L, Sassatelli, R, Cassetti, T, Giorgi Rossi, P, and Vicentini, M

Abstract

Introduction The epidemiology of lung cancer is changing worldwide, with smoking being the key driver of lung cancer incidence and mortality. Our aim is to analyze the incidence, survival and mortality trends in Italy in the framework of the 2017 survey on smoking behavior in Italy.Methods AIRTUM 2017 reports on cancer survival and incidence; 2017 survey on smoking behavior in Italy.Results Men achieved progress in lung cancer control characterized by a decrease in incidence and mortality and an increase in survival. The decreasing use of tobacco in men (from 60% in the 1960s to 24% in 2017) was most likely responsible for the decreasing incidence and mortality. Women showed no progress: although survival improved slightly, the incidence and mortality were both on the rise. This was most likely due to the increasing smoking rates in women in the 1970s and 80s. Of major concern is the accelerated rise in the number of smoking women from 4.6 million in 2016 to 5.7 million in 2017 compared to the decrease observed in men (from 6.9 to 6 million).Conclusions The incidence and mortality trends in males clearly demonstrate that primary prevention is the most effective way to reduce lung cancer mortality. By contrast, a 24% increase in the prevalence of smoking among women in just 1 year is extremely worrying for the future, and calls for immediate action by targeted strategies to reduce tobacco consumption in women and avert the dreadful prospect of a lung cancer epidemic in Italy.

Published
2017
Full Text
View/download PDF

12. GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY

Author

M. Puoti, G.B. Gaeta, T. Santantonio, Francesco Paolo Russo, Silvia Fargion, M. Siciliano, M. Di Gregorio, Salvatore Madonia, Pierluigi Toniutto, D. Ieluzzi, Loredana Falzano, Giuseppe Montalto, Luchino Chessa, Giuseppe Foti, Adriano Lazzarin, Gianpiero D'Offizi, Carmine Coppola, Gloria Taliani, Claudio Viscoli, Massimo Zuin, Maria Rendina, Antonio Craxì, Al Zignego, Giovanni Raimondo, V. De Maria, E.M. Erne, Mario Strazzabosco, Adele Giammario, M. Colombo, P. Andreone, Claudio Maria Mastroianni, Alessandro Federico, G. Angarano, Andrea Giacometti, Maria Cristina Vinci, Antonio Benedetti, Carlo Ferrari, Erica Villa, Floriano Rosina, Marcello Persico, G. Nardone, Marco Massari, M. Rumi, Liliana Chemello, Gabriella Verucchi, Ivan Gentile, M.G. Quaranta, Loreta A. Kondili, Guglielmo Borgia, M. Andreoni, Stefano Vella, Antonio Gasbarrini, Maurizia Rossana Brunetto, Pierluigi Blanc, Alessia Ciancio, Alfredo Alberti, Carlo Torti, A. Di Leo, Nicola Caporaso, Kondili, L, Quaranta, Mg, Falzano, L, Di Gregorio, M, Brunetto, M, Zignego, Al, Ciancio, A, Di Leo, A, Rendina, M, Raimondo, G, Ferrari, C, Craxi, A, Taliani, G, Borgia, Guglielmo, Gentile, Ivan, Santantonio, Ta, Giammario, A, Blanc, P, Gaeta, Gb, Gasbarrini, A, Siciliano, M, Chessa, L, Erne, Em, Ieluzzi, D, Russo, Fp, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Alberti, A, Puoti, M, Nardone, G, De Maria, V, Massari, M, Montalto, G, Foti, G, Rumi, Mg, Giacometti, A, Benedetti, A, D'Offizi, G, Strazzabosco, M, Fargion, S, Angarano, G, Federico, A, Caporaso, Nicola, Mastroianni, C, Toniutto, P, Colombo, M, Lazzarin, A, Torti, C, Andreoni, M, Rosina, F, Viscoli, C, Vella, S, and Villa, E.

Subjects
030203 arthritis & rheumatology, medicine.medical_specialty, Hepatology, business.industry, Chronic liver disease, medicine.disease, Surgery, 03 medical and health sciences, 0302 clinical medicine, Life evaluation, Internal medicine, medicine, 030211 gastroenterology & hepatology, business, Studio, Cohort study
Published
2016

13. Monumenti e luoghi della celebrazione nella città romana. Dall'età repubblicana al medio impero

Author

DE MARIA, SANDRO, S. DE MARIA, V. FORTUNATI, and S. De Maria

Subjects
CITTÀ, ETÀ ROMANA, SCULTURA, CELEBRAZIONE, MONUMENTO
Abstract

Il contributo esamina alcune fonti antiche sulla pratica della celebrazione attraverso statue e monumenti nel mondo romano. Analizza poi le strategie della dislocazione dei monumenti onorari nel contesto urbanistico delle città romane, attraverso lo studio specifico di alcuni casi particolari, sia in Italia che nel mondo provinciale. Propone alcune innovative chiavi di lettura in rapporto alla fruizione e alla "leggibilità" dei diversi monumenti, in un arco temporale esteso dall'età repubblicana al III secolo d.C.

Published
2010

14. Introduzione

Author

DE MARIA, SANDRO, FORTUNATI, VERA, S. DE MARIA, V. FORTUNATI, S. De Maria, and V. Fortunati

Subjects
ARCHITETTURA, MEMORIA, SCULTURA, MONUMENTO, PITTURA
Abstract

Sintesi dei problemi affrontati nei 25 contributi compresi nel volume, Atti di un Convegno tenuto a Bologna nell'ottobre del 2006.

Published
2010

15. La virtù dei governatori: monumenti onorari tardoantichi a Gortina e Afrodisia

Author

BALDINI, ISABELLA, S. DE MARIA, V. FORTUNATI, and I. Baldini Lippolis

Subjects
ARCHITETTURA, TARDA ANTICHITÀ, SCULTURA, EPIGRAFIA, ARCHEOLOGIA
Abstract

Analisi comparativa di due situazioni monumentali coeve, in cui si manifestano istanze autorappresentative delle élites locali. Il caso di Gortina viene illustrato sulla base delle nuove scoperte condotte nel corso di indagini archeologiche.

Published
2010

17. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Author

Antonio Ascione, null CLEO Study Group, Luigi Elio Adinolfi, Pietro Amoroso, Angelo Andriulli, Orlando Armignacco, Tiziana Ascione, Sergio Babudieri, Giorgio Barbarini, Michele Brogna, Francesco Cesario, Vincenzo Citro, Ernesto Claar, Raffaele Cozzolongo, Giuseppe D’Adamo, Emilio D’Amico, Pellegrino Dattolo, Massimo De Luca, Vincenzo De Maria, Massimo De Siena, Giuseppe De Vita, Antonio Di Giacomo, Rosanna De Marco, Giorgio De Stefano, Giulio De Stefano, Sebastiano Di Salvo, Raffaele Di Sarno, Nunzia Farella, Laura Felicioni, Basilio Fimiani, Luca Fontanella, Giuseppe Foti, Caterina Furlan, Francesca Giancotti, Giancarlo Giolitto, Tiziana Gravina, Barbara Guerrera, Roberto Gulminetti, Angelo Iacobellis, Michele Imparato, Angelo Iodice, Vincenzo Iovinella, Antonio Izzi, Alfonso Liberti, Pietro Leo, Gennaro Lettieri, Ileana Luppino, Aldo Marrone, Ettore Mazzoni, Vincenzo Messina, Roberto Monarca, Vincenzo Narciso, Lorenzo Nosotti, Adriano Maria Pellicelli, Alessandro Perrella, Guido Piai, Antonio Picardi, Paola Pierri, Grazia Pietromatera, Francesco Resta, Luca Rinaldi, Mario Romano, Angelo Rossini, Maurizio Russello, Grazia Russo, Rodolfo Sacco, Vincenzo Sangiovanni, Antonio Schiano, Antonio Sciambra, Gaetano Scifo, Filomena Simeone, Annarita Sullo, Pierluigi Tarquini, Paolo Tundo, Alfredo Vallone, Ascione, A, Adinolfi, Luigi Elio, Amoroso, P, Andriulli, A, Armignacco, O, Ascione, T, Babudieri, S, Barbarini, G, Brogna, M, Cesario, F, Citro, V, Claar, E, Cozzolongo, R, D'Adamo, G, D'Amico, E, Dattolo, P, De Luca, M, De Maria, V, De Siena, M, De Vita, G, Di Giacomo, A, De Marco, R, De Stefano, G, Di Salvo, S, Di Sarno, R, Farella, N, Felicioni, L, Fimiani, B, Fontanella, L, Foti, G, Furlan, C, Giancotti, F, Giolitto, G, Gravina, T, Guerrera, B, Gulminetti, R, Iacobellis, A, Imparato, M, Iodice, A, Iovinella, V, Izzi, A, Liberti, 1, Leo, P, Lettieri, G, Luppino, I, Marrone, Aldo, Mazzoni, E, Messina, V1, Monarca, R, Narciso, V, Nosotti, L, Pellicelli, Am, Perrella, A, Piai, G, Picardi, A, Pierri, P, Pietromatera, G, Resta, F, Rinaldi, L, Romano, M, Rossini, A, Russello, M, Russo, G, Sacco, R, Sangiovanni, V, Schiano, A, Sciambra, A, Scifo, G, Simeone, F, Sullo, A, Tarquini, P, Tundo, P, and Vallone, A.

Subjects
viruses, Hepatitis C virus, Observational Study, Antiviral therapy, Boceprevir, Chronic hepatitis, Peg-interferon, Ribavirin, Telaprevir, Hepatology, medicine.disease_cause, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Telaprevi, business.industry, Virology, Peg interferon, Chronic infection, chemistry, Chronic hepatiti, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

AIM:To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-TaqMan2.0 (Roche, LLQ 25 IU/mL). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57 (range 18-78), of whom 18.3% were over 65; mean body mass index 25.6 (range 16-39); genotype 1b (79.4%); diagnosis of cirrhosis (38.2%); and fibrosis F3/4 (71.2%). The following drugs were used: Telaprevir (66.2%) and PEG-IFN-alpha2a (67.6%). Patients were naïve (24.4%), relapsers (30.5%), partial responders (14.8%) and null responders (30.3%). Overall, adverse events (AEs) occurred in 617 patients (73.9%) during the treatment. Anemia was the most frequent AE (52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure (15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, non-responders to peginterferon + ribavirin.

Published
2016
Full Text
View/download PDF

18. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Author

Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D'Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, and Torti C

Abstract

Aim: To evaluate neutrophil gelatinase associated lipocalin (NGAL) in patients infected by hepatitis C virus (HCV) before and during treatment with directly acting antivirals (DAAs)., Methods: NGAL was measured in a group of patients with chronic HCV infection ranked, at baseline, by age, gender, anti-hypertensive therapy, HCV viral load, liver fibrosis stage and, either at baseline or after 1 year, estimated glomerular filtration rate (eGFR). Then, NGAL and eGFR evolutions were monitored in a subgroup of patients who started antiviral therapy with DAAs. Differences of median NGAL levels were evaluated through Wilcoxon-Mann-Whitney test for non-parametric data. Differences in dichotomous variables were evaluated through χ (2) test. At baseline, a univariate regression analysis was conducted to verify if NGAL values correlated with other quantitative variables [age, fibrosis four (FIB-4), AST to platelet ratio index (APRI), and eGFR]., Results: Overall, 48 patients were enrolled, 8 of them starting HCV treatment. At baseline, statistically significant differences were found in median NGAL values only between patients with eGFR < 60 mL/min vs patients with eGFR ≥ 90 mL/min. Differences in NGAL were not significant among patients ranked by HCV viral load, FIB-4 score and APRI, when patients with NGAL > 118.11 ng/dL were compared with those of NGAL ≤ 118.11 ng/dL, not statistically significant differences were present for age, gender, chronic kidney disease classification and liver fibrosis (P > 0.05). Linear correlation was found between NGAL and both age (P = 0.0475) and eGFR (P = 0.0282) values. Not statistically significant predictions of NGAL at baseline were demonstrated for eGFR evolution 1 year later. Interestingly, in the 8 patients treated with DAAs, median NGAL significantly increased at week 12 compared to baseline (P = 0.0239)., Conclusion: Our results suggest that NGAL should be further evaluated as an adjunct marker of kidney function in these patients.

Published
2016
Full Text
View/download PDF

19. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.

Author

Strazzulla A, Costa C, Pisani V, De Maria V, Giancotti F, Di Salvo S, Parisi SG, Basso M, Franzetti MM, Marascio N, Liberto MC, Barreca GS, Lamberti AG, Zicca E, Postorino MC, Matera G, Focà A, and Torti C

Subjects
Adult, Aged, Antiviral Agents therapeutic use, Drug Costs, Drug Therapy, Combination economics, Female, Genotype, Hepacivirus classification, Hepacivirus isolation & purification, Hepatitis C economics, Hepatitis C epidemiology, Hepatitis C virology, Humans, Interferon-alpha economics, Interferon-alpha therapeutic use, Italy epidemiology, Male, Middle Aged, Ribavirin economics, Ribavirin therapeutic use, Treatment Outcome, Young Adult, Antiviral Agents economics, Hepacivirus genetics, Hepatitis C drug therapy
Abstract

Background: In Italy, anti-HCV drugs are provided free of charge by the National Health System. Since 2011, three drug regimens including a directly acting antiviral (DAA) are considered the gold standard for HCV treatment. However, these drugs add a significant cost (roughly €26,000) to the combination of pegylated-interferon-α/ribavirin (PEG-IFN/RBV), which before DAA represented the unique treatment. To provide the National Health System potential useful information, we estimated costs to provide anti-HCV drugs to treat a population experienced for PEG-INF/RBV., Methods: Genotype 1 HCV mono-infected or HIV/HCV co-infected individuals who were treated with PEG-IFN/RBV between 2008 and 2013 were included. The cost to treat these patients with PEG-IFN/RBV was calculated (cost 1). We also estimated costs if we had to treat these patients with a lead-in period of PEG-INF/RBV followed by PEG-IFN/RBV and a DAA in naïves (cost 2), in addition to cost 1 plus the estimated cost to re-treat with PEG-IFN/RBV and a DAA patients who had a relapse or a non response (cost 3). Moreover, all costs were normalized by SVR. Rates of foreseen response with DAA were obtained from literature data., Results: The overall study population consisted of 104 patients. The rate of sustained virological response (SVR) was 55%, while it was estimated that SVR would be obtained in 75% of patients with a lead-in period with PEG-IFN/RBV followed by a DAA combination, and in 78% if this treatment is used to re-treat experienced patients with a DAA. Drug costs associated with these treatments were: €1,214,283 for cost 1, €3,474,977 for cost 2 and €3,002,095 for cost 3. Costs per SVR achieved were: €22,284 for cost 1, €44,643 for cost 2 and €38,322 for cost 3., Conclusions: Treatments including DAAs achieve a SVR in more patients than PEG-IFN/RBV but they cost around three times more than PEG-IFN/RBV alone regimens. Also, cost per SVR is almost twofold greater than PEG-IFN/RBV regimens. Therefore, it is mandatory to implement use of DAA in clinical practice, but the National Health System should allocate adequate resources to provide drugs, which challenges sustainability. Cost reduction for anti-HCV drugs should be pursued.

Published
2014
Full Text
View/download PDF

20. Update on epidemiology of HCV in Italy: focus on the Calabria Region.

Author

Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, and Focà A

Subjects
Genotype, Hepacivirus classification, Hepacivirus genetics, Hepacivirus isolation & purification, Hepatitis C virology, Humans, Italy epidemiology, Prevalence, Hepacivirus physiology, Hepatitis C epidemiology
Abstract

The epidemiological profile of HCV infection is evolving in Europe, as well as in Italy. We have previously showed genotype distributions and their dynamics in 2,153 HCV RNA positive patients living in Calabria, Southern Italy, over 11 years. In this study, we extend and update this information by evaluating a hospital-based cohort of 945 HCV RNA positive patients attending five hospitals in the Calabria Region from January 2011 to August 2013. We assessed rates of HCV genotypes according to age and gender and the dynamics of HCV genotype distribution over the 3-year period studied. Data showed that genotype 1b is the most prevalent, followed by subtypes 2a/2c and genotype 3. Genotype 4 exhibited an increase between 2011 and 2013. Also, we found a significant decrease in the median age of subjects infected with HCV genotype 3 and 4 during the period studied. Since HCV genotypes are important in epidemiology, pathogenesis and response to antiviral therapy, a continuous epidemiological surveillance is needed.

Published
2014
Full Text
View/download PDF

21. Hepatitis C virus cirrhosis: prolonged sustained virological response in a patient after low-dose antiviral treatment.

Author

Abenavoli L, De Maria V, De Siena M, Di Salvo S, Giancotti F, Gravina T, and Abenavoli SM

Subjects
Adult, Humans, Interferon alpha-2, Male, Recombinant Proteins, Antiviral Agents administration & dosage, Hepatitis C complications, Hepatitis C drug therapy, Interferon-alpha administration & dosage, Liver Cirrhosis virology, Polyethylene Glycols administration & dosage, Ribavirin administration & dosage
Abstract

Hepatitis C virus (HCV) infection is the most frequent cause of chronic liver disease in the western world. The ''gold standard'' treatment of chronic HCV infection currently involves the administration of pegylated interferon alpha (PEG-IFN) and ribavirin. The success of this therapy is demonstrated by sustained virological responses (SVR). Randomized trials and practice guidelines have reported that compensated HCV cirrhosis is an indication for treatment with PEG-IFN and ribavirin, not only to obtain SVR but also to increase survival and to reduce the development of cirrhotic sequelae. In particular, the literature has reported that antiviral treatment was associated with histological improvement of fibrosis in cirrhotic patients with SVR. Recently, the same authors have evaluated the efficacy and safety of different doses of antiviral treatment in patients with chronic HCV infection. The use of interferon has been limited due to associated side effects, particularly in cirrhotic patients. Consequently, therapeutic decisions should be made on an individual basis. The Authors report a case of a patient with compensated HCV liver cirrhosis, with associated severe thrombocytopenia and oesophageal varices, in which the administration of antiviral therapy at a dose lower than the therapeutic ''gold standard'' has achieved SVR and consequently improved clinical status.

Published
2008

22. [Familial intrahepatic cholestasis. Novel advances].

Author

Abenavoli L, De Maria V, DeSiena M, DiSalvo S, Giancotti F, Gravina T, and Abenavoli SM

Subjects
ATP-Binding Cassette Transporters genetics, Adenosine Triphosphatases genetics, Bile Acids and Salts metabolism, Cholestasis, Intrahepatic metabolism, Cholestasis, Intrahepatic therapy, Genetic Predisposition to Disease, Humans, Liver metabolism, Mutation, Cholestasis, Intrahepatic genetics
Abstract

In the last years hepatology has known remarkable improvement to understanding the mechanisms involved in familial intrahepatic cholestasis. The role of genetic anomalies is very important. Identification of genes involved in familial intrahepatic cholestasis has proven to be an important strategy to unravel the processes of bile acid synthesis and bile salt transport. The complexity of the mechanisms of bile flow clearly suggests that many more genetic abnormalities have yet to be identified.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results